Qu Biologics, Inc., a biotech company that specializes in formulating Site Specific Immunomodulators (SSI) for the restoration of normal immune system function, has just announced that a Data Safety Monitoring Committee (DSMC) has completed a review of one of their pipeline product's safety data from a 30-patient (50% enrollment) clinical trial. The product, QBECO SSI, is indicated for the treatment of Crohn's disease and has received clearance to proceed with further clinical research, which the committee will continue to monitor.
The company's ongoing trial plans to recruit a total of 60 US- and Canada-based participants diagnosed with moderate to severe Crohn's disease. The testing site will be situated in Vancouver, British Columbia, Canada, and is currently 60% enrolled. The DSMC is tasked with setting standards of safety, monitoring these standards' implementation for the trial participants and treatment efficacy data, and acting on behalf of patients whenever necessary.
"We are pleased to learn that safety data collected to date in our clinical trial has passed independent DSMC review," said Hall Gunn, Chief Executive Officer, Q